Sequella

About Sequella

Sequella, a clinical-stage pharmaceutical company, focuses on developing innovative therapeutics for infectious diseases, particularly multidrug-resistant tuberculosis (MDR-TB). The company operates in the global healthcare market, primarily targeting regions with high incidences of tuberculosis and other infectious diseases. Sequella's business model revolves around the research, development, and commercialization of novel drug candidates. The company generates revenue through licensing agreements, partnerships, and the eventual sale of its proprietary drugs. Sequella's lead product, SQ109, is currently in Phase 2b clinical trials for MDR-TB, demonstrating significant progress in combating this challenging disease. Additionally, Sequella has acquired exclusive worldwide rights to Pfizer's Sutezolid, another promising tuberculosis treatment in clinical development. The company also has a pipeline of drug candidates targeting fungal infections, Helicobacter pylori, nontuberculous mycobacteria, and Clostridium difficile. By focusing on these critical areas, Sequella aims to address unmet medical needs and improve global health outcomes.